This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Michael J. Fox Foundation Launches New Funding Opportunities For Parkinson's Research

NEW YORK, May 8, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) is today announcing the launch of three new funding programs focused on driving research toward transformative treatments and a cure for Parkinson's disease (PD). Two programs will promote critical work on the promising therapeutic targets LRRK2 and Parkin. A third program allows researchers to propose developing biomarkers of cognitive impairment in PD. The new funding opportunities are open to both academic and industry researchers.

In addition to these new programs, five other programs are currently open and accepting applications. Check out the complete list and apply for funding at

Brief descriptions of the three launching programs follow. 

LRRK2 Role in Idiopathic Parkinson's Disease 2013

MJFF invites proposals that can establish whether pathological mechanisms linked to LRRK2-associated parkinsonism underlie the more common idiopathic forms of PD. A clear answer to this question would provide additional insight into underlying causes of PD and greatly energize efforts to develop and test LRRK2-targeted therapeutics beyond those populations with established LRRK2 genetic parkinsonism.

Informational Conference Call: May 30, 2013, 12:00 p.m. ETPre-Proposals Due: June 19, 2013, 6:00 p.m. ET

To participate in the call and receive call-in details, please RSVP via email to

Parkin Biology & Therapeutic Development 2013

MJFF invites proposals that promote understanding of the biological function and therapeutic potential of Parkin. Mutations in the Parkin gene explain a large proportion of PD cases occurring before the age of 40 and could represent a promising therapeutic agent to alter the course of PD.

Informational Conference Call: June 6, 2013, 12:00 p.m. ETPre-proposals Due: June 19, 2013, 6:00 p.m. ET

To participate in the call and receive call-in details, please RSVP via email to

Cognition Biomarkers RFA 2013

MJFF invites proposals aimed at developing biomarkers of cognitive impairment in PD useful for future clinical trials. Particular emphasis will be on projects designed to develop biomarkers that identify transition between normal and impaired cognition, as well as between cognitive impairment and dementia.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs